Damning new evidence of pharma deceit (from the site of Flynn MP)

[Guest guest]

Damning new evidence of pharma deceit (from the site of Flynn

MP)

http://www.paulflynnmp.co.uk/newsdetail.jsp?id=411

" Our review of combined published and unpublished data for

paroxetine, sertraline, venlafaxine, and citalopram suggest that

these SSRIs are not efficacious in this context (treating depression

in children). Moreover, a possible increased risk of suicidal

ideation, serious adverse events, or both, although small, cannot be

ignored. "

That was the verdict of report published in the Lancet which reveals

comprehensive evidence of pharmaceutical companies failing to make

public drug trial results, which show their products in less than

favourable light. Earlier this year, this practice was exposed when

an internal document from GlaxoKline, revealed that data

demonstrating the ineffectiveness of Seroxat in treating depression

in children was not passed to regulators because it would undermine

the profile of the drug.

The study, an analysis of published and unpublished data of trials

of SSRIs in treating children with depression, reveals a staggering

manipulation of data. Unpublished trials were found to contain data

which show the drugs to be either ineffective or even dangerous.

Urgent reform to force the publication of all trials is needed.

The full report `Selective serotonin reuptake inhibitors in

childhood depression: systematic review of published versus

unpublished data' by Craig J Whittington, Tim Kendall, Fonagy,

Cottrell, Cotgrove, Ellen Boddington can be found at

www.thelancet.com.

[Guest guest]

Damning new evidence of pharma deceit (from the site of Flynn

MP)

http://www.paulflynnmp.co.uk/newsdetail.jsp?id=411

" Our review of combined published and unpublished data for

paroxetine, sertraline, venlafaxine, and citalopram suggest that

these SSRIs are not efficacious in this context (treating depression

in children). Moreover, a possible increased risk of suicidal

ideation, serious adverse events, or both, although small, cannot be

ignored. "

That was the verdict of report published in the Lancet which reveals

comprehensive evidence of pharmaceutical companies failing to make

public drug trial results, which show their products in less than

favourable light. Earlier this year, this practice was exposed when

an internal document from GlaxoKline, revealed that data

demonstrating the ineffectiveness of Seroxat in treating depression

in children was not passed to regulators because it would undermine

the profile of the drug.

The study, an analysis of published and unpublished data of trials

of SSRIs in treating children with depression, reveals a staggering

manipulation of data. Unpublished trials were found to contain data

which show the drugs to be either ineffective or even dangerous.

Urgent reform to force the publication of all trials is needed.

The full report `Selective serotonin reuptake inhibitors in

childhood depression: systematic review of published versus

unpublished data' by Craig J Whittington, Tim Kendall, Fonagy,

Cottrell, Cotgrove, Ellen Boddington can be found at

www.thelancet.com.

[Guest guest]

Damning new evidence of pharma deceit (from the site of Flynn

MP)

http://www.paulflynnmp.co.uk/newsdetail.jsp?id=411

" Our review of combined published and unpublished data for

paroxetine, sertraline, venlafaxine, and citalopram suggest that

these SSRIs are not efficacious in this context (treating depression

in children). Moreover, a possible increased risk of suicidal

ideation, serious adverse events, or both, although small, cannot be

ignored. "

That was the verdict of report published in the Lancet which reveals

comprehensive evidence of pharmaceutical companies failing to make

public drug trial results, which show their products in less than

favourable light. Earlier this year, this practice was exposed when

an internal document from GlaxoKline, revealed that data

demonstrating the ineffectiveness of Seroxat in treating depression

in children was not passed to regulators because it would undermine

the profile of the drug.

The study, an analysis of published and unpublished data of trials

of SSRIs in treating children with depression, reveals a staggering

manipulation of data. Unpublished trials were found to contain data

which show the drugs to be either ineffective or even dangerous.

Urgent reform to force the publication of all trials is needed.

The full report `Selective serotonin reuptake inhibitors in

childhood depression: systematic review of published versus

unpublished data' by Craig J Whittington, Tim Kendall, Fonagy,

Cottrell, Cotgrove, Ellen Boddington can be found at

www.thelancet.com.

[Guest guest]

Damning new evidence of pharma deceit (from the site of Flynn

MP)

http://www.paulflynnmp.co.uk/newsdetail.jsp?id=411

" Our review of combined published and unpublished data for

paroxetine, sertraline, venlafaxine, and citalopram suggest that

these SSRIs are not efficacious in this context (treating depression

in children). Moreover, a possible increased risk of suicidal

ideation, serious adverse events, or both, although small, cannot be

ignored. "

That was the verdict of report published in the Lancet which reveals

comprehensive evidence of pharmaceutical companies failing to make

public drug trial results, which show their products in less than

favourable light. Earlier this year, this practice was exposed when

an internal document from GlaxoKline, revealed that data

demonstrating the ineffectiveness of Seroxat in treating depression

in children was not passed to regulators because it would undermine

the profile of the drug.

The study, an analysis of published and unpublished data of trials

of SSRIs in treating children with depression, reveals a staggering

manipulation of data. Unpublished trials were found to contain data

which show the drugs to be either ineffective or even dangerous.

Urgent reform to force the publication of all trials is needed.

The full report `Selective serotonin reuptake inhibitors in

childhood depression: systematic review of published versus

unpublished data' by Craig J Whittington, Tim Kendall, Fonagy,

Cottrell, Cotgrove, Ellen Boddington can be found at

www.thelancet.com.